The collaboration brings together instrumentation with expression technology to create what the firms say is “the most efficient cell line development solution for biotherapeutic drug developers yet.”
The collaboration – financials of which have not been divulged – aims at overcoming the bottlenecks in biomanufacturing by establishing and isolating the most suitable cell lines for a drug candidate.
The combined offering will appeal to “pharmaceutical and biopharma companies wanting to shorten their cell line development timelines and make sure they get high producing clones,” Ian Taylor, sales & marketing director at Solentim, told this publication.
He added the partnership creates “the most efficient cell line development solution for biotherapeutic drug developers yet,” meaning “that we can get at the highest producers in the population without using fluorescence detection assays for secretion of protein by cells. “All the cells that survive and are single cell seeded will be high producers.”
The approach, he argued, avoids the need to pre-screen for high producing clones.
According to Taylor, ATUM brings its molecular biology expertise and its proprietary Leap-In Transposase expression technology to the partnership, while Solentim provides its single cell VIPS (verified in-situ plate seeding) seeding instrumentation, providing assurance of clonality documentation.